Non-Invasive Prenatal Testing (NIPT) Market: Current Analysis and Forecast (2021-2027)

Non-Invasive Prenatal Testing (NIPT) Market: Current Analysis and Forecast (2021-2027)

Non-Invasive Prenatal Testing (NIPT) Market is anticipated display a CAGR of around 14.7% over the forecast period (2021-2027). Mutations in genes and chromosomes can increase the risk of genetic abnormalities in an unborn child. The rising prevalence of chromosomal abnormalities has resulted in a surge in demand for a reliable screening tool for prenatal tests. The high risk of chromosomal abnormalities with increasing maternal age, a growing preference for non-invasive techniques over invasive methods, and an improving reimbursement scenario for NIPT are the crucial factors driving the market growth. Several established players as well as new start-ups are looking for funding to conduct research and clinical testing on NIPT techniques. Many government and private organizations are keenly looking for research institutes and start-ups for the development of innovative testing procedures to detect key genetic disorders through NIPT. For instance, in June 2019, Cradle Genomics, a San-Diego-based start-up, raised over US$ 17 Mn in Series A funding carried out to support clinical development, corporate infrastructure, CLIA lab operations, and commercial launch of the tests.

Insights Presented in the Report
"Amongst Product, Consumables segment held significant market share in 2020”

Based on product, the market is categorized into instruments and consumables. The consumables segment is further segmented into assay kits & reagents and disposables. Assay kits & reagents includes ultrasound transmission gel, cleaning solution etc. The disposables comprises of swipes, cottons, hand gloves, etc. The high demand for consumables attributes to market participants introducing new test kits and the increasing number of lab-based tests performed globally. Furthermore, one of the major factors driving and fueling demand for reagents and consumables is the increasing number of research and development activities for screening genetic disorders. Technological advancements in instruments, as well as increased collaboration among players, are other crucial factors proliferating the global adoption of consumables for the detection of abnormalities during pregnancy.
"Amongst Method, Cell-Free DNA in Maternal Plasma Tests to acquire largest market share”

Based on the method, the market is bifurcated into Ultrasound Detection, Biochemical Screening Tests, and Cell-Free DNA in Maternal Plasma Tests. Of these three, Cell-Free DNA in Maternal Plasma Tests acquires the largest share of the Non-Invasive Prenatal Testing (NIPT) Market. The segment's rapid growth can be attributed to technological advancements and increased company initiatives to develop new products. Cell-free DNA is increasingly being used in prenatal care to predict the risk of genetic conditions using various genetic analyses. Several research studies are being conducted to advance the use of tests available through this method. For example, Togneri et al. published a study in December 2019 that implemented and validated cell-free DNA-based NIPT in the National Health Service (NHS) regional genetics laboratory. The researchers concluded that cfDNA-based NIPT can be performed as a private test in patients with a low risk of common trisomy or for other reasons.
"North America will Dominate the Market During the Forecast Period”

For a better understanding of the market adoption of Non-Invasive Prenatal Testing (NIPT), the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and Rest of North America), Europe (Germany, France, Italy, United Kingdom and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), and Rest of World. In 2020, North America region held the highest market share in the global Non-Invasive Prenatal Testing (NIPT) market. Some of the major players operating in the market are Illumina, Inc., Yourgene Health, Natera, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Laboratory Corporation of America, Eurofins LifeCodexx GmbH, Centogene N.V., Quest Diagnostics Incorporated, Agilent Technologies, Inc.

Reasons to buy this report:

  • The study includes market sizing and forecasting analysis validated by authenticated key industry experts
  • The report presents a quick review of overall industry performance at one glance
  • The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
  • Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
  • The study comprehensively covers the market across different segments
  • Deep dive regional level analysis of the industry


1 MARKET INTRODUCTION
1.1. Market Definitions
1.2. Limitation
1.3. Stakeholders
1.4. Currency used in Report
2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1. Research Process of the Non-Invasive Prenatal Testing (NIPT) Market
2.2. Research Methodology of the Non-Invasive Prenatal Testing (NIPT) Market
2.3. Forecasting Method
2.4. Respondent Profile
2.5. Main Objective of the Non-Invasive Prenatal Testing (NIPT) Market Study
3 MARKET SYNOPSIS
4 EXECUTIVE SUMMARY
5 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET COVID-19 IMPACT
6 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET REVENUE (USD BN), 2019-2027F
7 MARKET INSIGHTS BY PRODUCT
7.1. Instruments
7.1.1. Ultrasound Devices
7.1.2. Next-Generation Sequencing Systems
7.1.3. Polymerase Chain Reaction Instruments
7.1.4. Microarrays
7.1.5. Others
7.2. Consumables
7.2.1. Assay Kits & Reagents
7.2.2. Disposables
8 MARKET INSIGHTS BY METHOD
8.1. Ultrasound Detection
8.2. Biochemical Screening Tests
8.3. Cell-Free DNA in Maternal Plasma Tests
9 MARKET INSIGHTS BY APPLICATION
9.1. Trisomy Detection
9.2. Microdeletion Detection
9.3. Others
10 MARKET INSIGHTS BY END-USER
10.1. Hospitals & Clinics
10.2. Diagnostic Laboratories
10.3. Others
11 MARKET INSIGHTS BY REGION
11.1. North America
11.1.1. US
11.1.2. Canada
11.1.3. Rest of North America
11.2. Europe
11.2.1. Germany
11.2.2. UK
11.2.3. France
11.2.4. Italy
11.2.5. Rest of Europe
11.3. Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. Australia
11.3.5. South Korea
11.3.6. Rest of Asia-Pacific
11.4. Rest of World
12 NON-INVASIVE PRENATAL TESTING (NIPT)MARKET DYNAMICS
12.1. Market Drivers
12.2. Market Challenges
12.3. Impact Analysis
13 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET OPPORTUNITIES
14 NON-INVASIVE PRENATAL TESTING (NIPT) MARKET TRENDS
15 LEGAL & REGULATORY FRAMEWORK
16 DEMAND AND SUPPLY SIDE ANALYSIS
16.1. Demand Side Analysis
16.2. Supply Side Analysis
16.2.1. Top Product Launches
16.2.2. Top Business Partnerships
16.2.3. Top Business Expansions
16.2.4. Top Merger and Acquisitions
17 COMPETITIVE SCENARIO
17.1. Competitive Landscape
17.1.1. Company Shares, By Revenue
18 COMPANY PROFILED
18.1. Illumina, Inc.
18.2. Yourgene Health
18.3. Natera
18.4. F. Hoffmann-La Roche Ltd
18.5. PerkinElmer Inc.
18.6. Laboratory Corporation of America
18.7. Eurofins LifeCodexx GmbH
18.8. Centogene N.V.
18.9. Quest Diagnostics Incorporated
18.10. Agilent Technologies, Inc.
19 DISCLAIMER

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings